Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
Portfolio Pulse from
Biogen and Stoke Therapeutics have entered a collaboration to develop and commercialize Zorevunersen for Dravet Syndrome. Stoke retains rights in North America, while Biogen gains rights elsewhere. The partnership expands Biogen's rare disease pipeline.
February 18, 2025 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen has partnered with Stoke Therapeutics to develop Zorevunersen for Dravet Syndrome, expanding its rare disease pipeline. Biogen gains commercialization rights outside North America.
The collaboration with Stoke Therapeutics allows Biogen to expand its rare disease pipeline, which is a strategic move to strengthen its position in the market for high-value, disease-modifying medicines. The exclusive commercialization rights outside North America provide Biogen with a significant opportunity to capture market share globally.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Stoke Therapeutics partners with Biogen to develop Zorevunersen, retaining rights in North America and receiving $165M upfront, with potential for $385M in milestones.
Stoke Therapeutics benefits from the partnership with Biogen by retaining North American rights and receiving significant financial support, including an upfront payment and potential milestone payments. This collaboration enhances Stoke's financial position and development capabilities.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90